
CME Group Nets $1.55B from OSTTRA Sale Amid 6% Nine-Month Revenue Growth
CME Group Inc.Description
What this story covers
CME Group's Q3 2025 10-Q shows $1.53B revenue (down 3% YoY) but 6% nine-month growth to $4.87B, driven by diversified volumes and higher fees. Net income up 9% YTD to $2.85B. Strong liquidity with $151.5B cash position; $1.55B OSTTRA sale boosts Q4. Stable risks, tech investments enhance strategy.
Story snapshot
CompanyCME Group Inc.
TickerCME
VariantStandard detailed
Duration14:05
Filing type10-Q
PeriodQ3 2025
IndustryFinancial Services
Accession0001156375-25-000206
Full Story Script
Content not available for this story.